替加环素联合头孢哌酮-舒巴坦治疗医院获得性泛耐药鲍氏不动杆菌肺炎10例

发布时间：2018-04-09 12:04

本文选题：鲍氏不动杆菌　切入点：医院获得性肺炎　出处：《中国新药与临床杂志》2014年03期

【摘要】：目的了解替加环素联合头孢哌酮-舒巴坦治疗医院获得性泛耐药鲍氏不动杆菌肺炎的临床疗效和安全性。方法回顾分析本院2011年9月1日至2013年2月28日采用替加环素治疗的医院获得性鲍氏不动杆菌肺炎病例的临床治疗资料、治疗结果及不良反应情况。结果采用替加环素初始治疗及挽救治疗的10例医院获得性泛耐药鲍氏不动杆菌肺炎患者均联用了头孢哌酮-舒巴坦(3.0 g,q8 h~q6 h),疗程为4~20 d。其中替加环素常规维持剂量(50 mg,q12 h)治疗3例均治愈;替加环素加大维持剂量(75 mg~100 mg,q12 h)治疗7例,2例治愈,3例显效,2例无效死亡。总有效率为80%。不良反应主要表现为恶心、呕吐及腹泻等胃肠道症状,症状均较轻,对症治疗可缓解。结论替加环素联合头孢哌酮-舒巴坦治疗医院获得性泛耐药鲍氏不动杆菌肺炎有效、安全。
[Abstract]:Objective to investigate the efficacy and safety of tegicycline combined with cefoperazone-sulbactam in the treatment of hospital acquired pandrug-resistant Acinetobacter baumannii pneumonia.Methods the clinical data, treatment results and adverse reactions of patients with acinetobacter baumannii pneumonia treated with tegacycline from September 1, 2011 to February 28, 2013 were retrospectively analyzed.Results Ten patients with nosocomial pandrug-resistant Acinetobacter baumannii pneumonia who were treated with tegacycline initial treatment and rescue therapy were all treated with cefoperazone-sulbactam 3.0 g / g Q8 h~q6 HX for 420 days.The routine maintenance dose of tegicycline was 50 mg / q12 h (all 3 cases were cured), and 7 cases (2 cases) were cured by tegacycline plus maintenance dose (75 mg~100 / g Q12 h) and 2 cases died of failure.The total effective rate is 80.The main adverse reactions were nausea, vomiting, diarrhea and other gastrointestinal symptoms.Conclusion tigicycline combined with cefoperazone-sulbactam is effective and safe in the treatment of hospital acquired pan-resistant Acinetobacter baumannii pneumonia.
【作者单位】：中山大学附属第三医院内科ICU;
【分类号】：R563.1

【参考文献】